# Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/tocilizumab-and-covid-19-a-meta-analysis-of-2120-patients-with-severe-disease/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Azza Sarfraz,Zouina Sarfraz,Muzna Sarfraz,Hinna Aftab,Zainab Pervaiz |
| Citations | 27 |
| DOI | 10.3906/sag-2010-131 |
| Fields | Medicine |
| Open Access | true |
| OA Status | diamond |
| OA URL | https://journals.tubitak.gov.tr/cgi/viewcontent.cgi?article=1196&context=medical |
| OpenAlex ID | https://openalex.org/W3109543290 |
| PMID | 33244947 |
| Type | review |
| Year | 2020 |

## Paper authors

- [Muzna Sarfraz](https://scholariq.org/researchers/muzna-sarfraz/)

## Paper primary topic

- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)

## Paper topics

- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [Long-Term Effects of COVID-19](https://scholariq.org/topics/long-term-effects-of-covid-19/)
- [SARS-CoV-2 and COVID-19 Research](https://scholariq.org/topics/sars-cov-2-and-covid-19-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.